Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      SynKIR-310 for Relapsed/Refractory B-NHL
      Description

      This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

      Conditions
      B Cell LymphomaNHL, AdultMantle Cell LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaAggressive B-Cell Non-Hodgkin LymphomaIndolent B-Cell Non-Hodgkin LymphomaFollicular LymphomaMarginal Zone LymphomaDLBCL - Diffuse Large B Cell LymphomaHGBL with MYC and BCL2 And/or BCL6 RearrangementsHigh-grade B-cell LymphomaDiffuse Large B Cell LymphomaLarge B-cell LymphomaT-Cell/Histiocyte Rich LymphomaNon-hodgkin Lymphoma,B CellPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Epstein-Barr Virus Positive DLBCL, NosFollicular Lymphoma Grade 3BDLBCL (Diffuse Large B-Cell Lymphoma) Associated with Chronic InflammationHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedFollicular Lymphoma Grade 3Marginal Zone Splenic LymphomaDLBCL
      Talk to us
      TERMINATED
      An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
      Description

      A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

      Conditions
      Epstein-Barr Virus Associated Lymphoproliferative DisorderEBV-Related PTLDEBV Related Non-Hodgkin's LymphomaEBV-Positive DLBCL, NOSEBV Associated LymphomaEBV Related PTCL, NOS
      Talk to us